← Markets

Inhibrx Biosciences Inc.

INBX · NASDAQ

Market closed$87.39$-1.68 (-1.89%)After hours $87.39 · 0.00%

Key statistics

Previous close$89.07
Open$85.76
Day high$91.52
Day low$85.21
52-week high$155.29
52-week low$20.55
Market cap1.28B
Volume271.69K
Average volume470.74K
P/E ratio-10.42
Forward P/E—
EPS-8.39
Dividend yield0.00%

Market context

Why it moved

Inhibrx Biosciences (INBX) saw its stock decline as broader market sentiment turned negative amid tech sector selloffs, overshadowing the company's recently announced expanded loan agreement with Oxford Finance that increased its total credit facility to $500 million.

MagnoliatribuneInstagramPayloadspaceWearealignedInvestors

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Inhibrx Biosciences closed lower amid a broader tech and healthcare selloff, with the XLV health care ETF also declining on the day. The stock pulled back after a significant catalyst earlier this week: on July 16, the company announced an amended loan agreement with Oxford Finance, expanding its total credit facility to $500 million, a move that bolsters its financial runway as it advances its oncology pipeline. Investor attention remains on the company's high-profile cancer assets, including INBRX-106 — which drew reported Big Pharma interest from Merck and Ono Pharmaceutical in April — and Ozekibart, which showed a 20% response rate in advanced colorectal cancer, well above standard-of-care benchmarks.

-1.8862

July 13, 2026Inhibrx Biosciences edged lower in regular trading and continued slipping in after-hours, underperforming the broader healthcare sector (XLV essentially flat in extended hours) as macro headwinds — including renewed U.S.-Iran tensions, a chip stock selloff, and a cautious start to Q2 earnings season — weighed on small-cap biotech names. The stock also came off a sharp -10.45% decline on July 10, with investors reassessing the name after its April surge above record highs driven by reported M&A interest from Merck and Ono Pharmaceutical in INBRX-106 (valued potentially at $8B+) and strong ozekibart colorectal cancer data. A late-June Russell index reclassification into growth benchmarks adds a new investor base, but near-term focus remains on the FDA BLA review of ozekibart for chondrosarcoma and a planned Phase 3 move for INBRX-106.

-0.9085

July 11, 2026Inhibrx Biosciences tumbled over 10% as the clinical-stage biotech gave back recent gains despite a broader sector tailwind, with biotech broadly cited as a market leader by commentators including Jim Cramer. The pullback follows a strong run tied to the company's recent reclassification into Russell growth indexes — a shift analysts note has reframed its investment story — though valuation remains contested given its $130M+ annual losses and minimal revenue against a consensus analyst price target of $150. Shares are recovering modestly in after-hours trading.

-10.4381

July 10, 2026Inhibrx Biosciences surged nearly 7%, closing at $103.85 on above-average volume, as the clinical-stage biotech rode a powerful tailwind from the broader sector rally. Jim Cramer called biotech 'the hottest group in the market,' predicting a wave of M&A deals amid a more favorable FDA regulatory environment, while healthcare stocks posted their second consecutive week of market-leading gains. Adding fuel, INBX was recently reclassified into growth-oriented Russell indices, signaling a sentiment shift; the stock carries a consensus analyst price target of $277.50 — more than 160% above current levels — though it remains pre-revenue with a $130M annual loss.

6.9516

July 9, 2026Inhibrx Biosciences fell amid a broad market risk-off selloff triggered by President Trump declaring the U.S.-Iran ceasefire 'over,' sending oil prices surging 5%+ and dragging major indices lower. Adding company-specific context, Inhibrx was recently reclassified into Russell growth indices following the annual reshuffle — a sign of sentiment shifting toward its higher-growth profile — while Jim Cramer flagged biotech as 'the hottest group in the market,' predicting a wave of M&A deals under the new FDA leadership, potentially boosting acquisition interest in clinical-stage names like Inhibrx. Despite strong 30-day momentum (+15.8%) and an analyst price target of $277.50, the stock carries elevated valuation risk with minimal revenue and $130M in annual losses.

-3.6228

June 30, 2026Inhibrx Biosciences edged higher, supported by a pair of Russell index developments — being dropped from the Russell 2000 Defensive Index while simultaneously added to the Russell 3000E Growth Benchmark — reflecting the market's evolving view of INBX as a growth-oriented name. The moves follow the FDA's acceptance of the Biologics License Application for ozekibart in unresectable or metastatic chondrosarcoma, a major regulatory milestone that has driven a 62% share price gain over the past 90 days, even as analysts note the stock still trades well below the consensus price target of $277.50.

0.7278

June 24, 2026Inhibrx Biosciences gained ground as the FDA's acceptance of its Biologics License Application for ozekibart (INBRX-109) — targeting unresectable or metastatic conventional chondrosarcoma — shifted investor sentiment, establishing a defined regulatory catalyst with a PDUFA decision date of April 14, 2027. The BLA acceptance, backed by the ChonDRAgon trial showing statistically significant progression-free survival improvement, builds on earlier momentum from Big Pharma deal interest in INBRX-106 and promising colorectal cancer data, even as investors remain mindful of the company's ongoing cash burn and negative equity position.

2.4002

June 22, 2026Inhibrx Biosciences closed modestly higher, edging up as investor focus remains on the company's regulatory momentum following the FDA's recent acceptance of its Biologics License Application for ozekibart in unresectable or metastatic conventional chondrosarcoma. Shares have surged roughly 53% over the past 90 days but pulled back about 15% over the last month, suggesting near-term momentum has cooled after the initial ozekibart filing catalyst. Adding to the longer-term narrative, a Reuters report from April highlighted early-stage Big Pharma interest—including Merck—in pipeline asset INBRX-106, with potential deal value estimated above $8 billion, keeping M&A speculation alive even as today's session saw below-average volume and broader Nasdaq weakness dragged by megacap tech declines.

0.2687

Seeking Alpha · July 17, 2026Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX)TradingView · July 16, 2026Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues WarrantsPR Newswire · July 16, 2026Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 MillionInvesting.com · July 16, 2026Inhibrx expands credit facility to $500 million with OxfordSimply Wall Street · July 10, 2026Does Inhibrx Biosciences' (INBX) Shift Into Russell Growth Indexes Reframe Its Core Investment Story?Investing.com · June 2, 2026Stifel reiterates Inhibrx Biosciences stock rating on durability dataPR Newswire · May 14, 2026Inhibrx Reports First Quarter 2026 Financial ResultsPR Newswire · May 11, 2026Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Benzinga · June 15, 2026Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027
Benzinga · May 14, 2026Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate
Benzinga · May 11, 2026Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Mt Newswire · May 11, 2026Inhibrx Says INBRX-106 With Pembrolizumab Achieves Higher Response Rate in Phase 2 Trial
Benzinga · May 11, 2026Inhibrx Reports Interim Phase 2 Data For INBRX-106 In First-Line HNSCC
Benzinga · April 22, 2026Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Mt Newswire · April 22, 2026Update: Market Chatter: Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug
Mt Newswire · April 22, 2026Update: Market Chatter: Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug

Peers

S&P 500SPX · $7,457.69-1.01%Xencor, Inc.XNCR · $17.47+16.86%Immunocore Holdings plcIMCR · $34.96+1.42%Sarepta Therapeutics, Inc.SRPT · $17.22-0.06%Kodiak Sciences Inc.KOD · $42.64+3.37%UroGen Pharma Ltd.URGN · $40.23+0.56%Nanobiotix S.A.NBTX · $37.79+0.69%Oruka Therapeutics, Inc.ORKA · $92.70+11.63%Legend Biotech CorporationLEGN · $22.26-1.98%CRISPR Therapeutics AGCRSP · $47.78-1.63%BridgeBio Pharma, Inc.BBIO · $81.38+1.34%Ionis Pharmaceuticals, Inc.IONS · $54.39-0.48%